Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protara Therapeutics (TARA) Current Assets (2016 - 2026)

Protara Therapeutics' Current Assets history spans 14 years, with the latest figure at $140.0 million for Q1 2026.

  • Quarterly Current Assets rose 10.64% to $140.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $140.0 million through Mar 2026, up 10.64% year-over-year, with the annual reading at $159.5 million for FY2025, 7.35% down from the prior year.
  • Current Assets came in at $140.0 million for Q1 2026, down from $159.5 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $172.2 million in Q4 2024 to a low of $57.9 million in Q1 2024.
  • The 5-year median for Current Assets is $94.6 million (2023), against an average of $105.7 million.
  • The largest YoY upside for Current Assets was 150.57% in 2024 against a maximum downside of 38.79% in 2024.
  • Protara Therapeutics' Current Assets stood at $86.1 million in 2022, then dropped by 20.25% to $68.7 million in 2023, then skyrocketed by 150.57% to $172.2 million in 2024, then dropped by 7.35% to $159.5 million in 2025, then dropped by 12.23% to $140.0 million in 2026.
  • Per Business Quant, the three most recent readings for TARA's Current Assets are $140.0 million (Q1 2026), $159.5 million (Q4 2025), and $135.6 million (Q3 2025).